Totally implanted venous access-associated adverse events in oncology: Results from a prospective 1-year surveillance programme.
暂无分享,去创建一个
F. Guisier | P. Michel | F. Di Fioré | V. Merle | P. Czernichow | D. Sefrioui | R. de Mil | M. Lucas | T. Vermeulin | A. Loeb | H. Marini | H. Daubert | M. Lottin | C. Gray
[1] J. Muir,et al. Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy , 2016, Supportive Care in Cancer.
[2] C. Ferreccio,et al. Heart Failure in Rural Communities. , 2015, Heart failure clinics.
[3] T. Seo,et al. Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports , 2014, Korean journal of radiology.
[4] Ethan A. Halm,et al. Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review , 2013, Journal of General Internal Medicine.
[5] P. Vanhems,et al. Totally implantable central venous access port infections in patients with digestive cancer: incidence and risk factors. , 2012, American journal of infection control.
[6] P. Cassier,et al. Infections associées aux chambres à cathéter implantables, épidémiologie et prévention : revue de la littérature , 2012 .
[7] S. Ahn,et al. Ultrasound and Fluoroscopy-Guided Placement of Central Venous Ports via Internal Jugular Vein: Retrospective Analysis of 1254 Port Implantations at a Single Center , 2012, Korean journal of radiology.
[8] L. Rasero,et al. The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study. , 2011, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[9] J. Yoshida,et al. Association between risk of bloodstream infection and duration of use of totally implantable access ports and central lines: a 24-month study. , 2011, American journal of infection control.
[10] G. Quéré,et al. [Percutaneous implantable port-related infection and thrombosis: diagnostic and management]. , 2011, Bulletin du cancer.
[11] A. Lefort,et al. Complications infectieuses liées aux chambres implantables : caractéristiques et prise en charge , 2010 .
[12] C. Heibl,et al. Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. , 2010, European journal of cancer care.
[13] M. Prins,et al. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. , 2010, Thrombosis research.
[14] N. Wolosker,et al. Totally Implantable Ports Connected to Valved Catheters for Chemotherapy: Experience from 350 Groshong Devices , 2010 .
[15] D. Lebeaux,et al. [Totally implanted access port-related infections: features and management]. , 2010, La Revue de medecine interne.
[16] Ming-Shian Lu,et al. Analysis of risk factors for central venous port failure in cancer patients. , 2009, World journal of gastroenterology.
[17] J. Favre,et al. Incidence, prévalence et facteurs de risque de survenue d’une première complication infectieuse sur chambres à cathéter implantables , 2009 .
[18] C. Righini,et al. Complications d'un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures , 2009 .
[19] F. Rosendaal,et al. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Hochhauser,et al. A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).
[21] A. Loh,et al. Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity? , 2007, Journal of pediatric surgery.
[22] S. Boutreux,et al. Social determinants of access to reference care centres for patients with colorectal cancer--a multilevel analysis. , 2006, European journal of cancer.
[23] Dan M. Kluger,et al. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. , 2006, Mayo Clinic proceedings.
[24] M. Levine,et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Rubie,et al. Utilisation des sites veineux implantables dans les chimiothérapies massives en pédiatrie , 2006 .
[26] S. Boutreux,et al. Social and geographic disparities in access to reference care site for patients with colorectal cancer in France , 2005, British Journal of Cancer.
[27] B. Asselain,et al. Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie : un score de risque prédictif? , 2005 .
[28] F. Rosendaal,et al. The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.
[29] J. Petit,et al. Cathéters à chambre implantable : épidémiologie des complications et étude microbiologique des dispositifs après ablation , 2004 .
[30] P. Saip,et al. Totally implantable venous-access ports: local problems and extravasation injury. , 2002, The Lancet. Oncology.
[31] D. Maki,et al. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] A. Macrez,et al. Long-Term Central Venous Catheter Infection in HIV-infected and Cancer Patients: A Multicenter Cohort Study , 1999, Infection Control & Hospital Epidemiology.